Browse the evidence

Visceral obesity is a critical risk factor for cardiovascular disease, often present in individuals with normal BMI, leading to underestimation of cardiovascular risk in clinical practice.

Don't rely solely on BMI. If you have a family history of heart disease, ask for a waist circumference measurement or visceral fat assessment, as 'normal weight' obesity can still cause heart attacks.

Tirzepatide (dual GLP-1/GIP agonist) produces superior weight loss compared to semaglutide in patients with type 2 diabetes.

For patients with type 2 diabetes, tirzepatide (5-15 mg weekly) may offer better weight loss (8.5-12.4%) than semaglutide (6.7%). However, it is not yet registered for obesity treatment in Poland, so access may be limited.

Bariatric surgery is the most effective, sustainable, and generally safe therapy for severe obesity (BMI ≥ 35 kg/m²) when lifestyle and pharmacological treatments have failed.

For severe obesity (BMI ≥ 35) where lifestyle and drug treatments have failed, bariatric surgery is the most effective and sustainable option. It is indicated for BMI > 30 with type 2 diabetes. Risks must be carefully weighed against benefits, and lifelong follow-up is required.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater weight loss than Semaglutide in patients with type 2 diabetes.

If you have type 2 diabetes and obesity, ask your doctor about Tirzepatide. It is a once-weekly injection that combines two hormones to help you lose more weight than Semaglutide. It starts at a low dose and increases every few weeks to reach the maximum dose.

Bariatric surgery (Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass) provides effective and sustainable weight loss, with Roux-en-Y showing greater long-term excess weight loss but higher morbidity.

If you have severe obesity (BMI >40 or >35 with health issues), surgery is a highly effective option. Gastric Bypass leads to more weight loss than Sleeve Gastrectomy but has higher risks. Discuss the trade-offs with your surgeon.

Both intensive behavioral group intervention and brief individual counseling result in small, similar weight loss over 5 years, suggesting that regular follow-up and person-centered care may promote weight maintenance.

Regular medical check-ins and basic dietary advice can help maintain weight in middle age. You do not necessarily need complex programs to achieve modest, sustainable results.

Tirzepatide provides significant cardiovascular, hepatic, and renal benefits in obese patients, including improved lipid profiles, reduced blood pressure, and potential protection against NAFLD/NASH and CKD progression.

Beyond weight loss, Tirzepatide improves heart health by lowering blood pressure and cholesterol, and may protect the liver (NAFLD/NASH) and kidneys (CKD). These benefits are observed alongside weight loss but may also stem from direct hormonal effects.

Maintaining weight loss is significantly harder than losing it due to physiological mechanisms (AgRP neuron activation, leptin resistance) that drive weight regain, requiring sustained energy deficit and often pharmacological support.

Expect your body to fight back after you lose weight. Biological mechanisms like increased hunger signals (AgRP neurons) will try to restore your previous weight. To counter this, you need a sustained energy deficit, possibly aided by medication, and consistent lifestyle habits. Maintenance is a biological battle, not just a mental one.

Dietary fiber intake must be accompanied by adequate water intake to prevent constipation, a common adverse event of anti-obesity medications.

When taking weight loss medications, increase your intake of fruits, vegetables, and whole grains for fiber, but you MUST drink more water. Without enough fluid, high fiber can cause constipation, which is already a common side effect of these drugs.

Early combination therapy using low-hypoglycemia-risk agents (e.g., SGLT2 inhibitors or GLP-1 receptor agonists) combined with metformin at diagnosis is more effective than sequential stepwise therapy at maintaining glycemic targets and minimizing diabetes-related complications.

If you have just been diagnosed with Type 2 Diabetes, ask your doctor about starting with a combination of Metformin and another modern drug (like an SGLT2 inhibitor or GLP-1 agonist) right away, rather than waiting for your blood sugar to rise again. This approach keeps your blood sugar closer to normal levels for longer and protects your heart and kidneys better than starting with just one drug.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) produce significant weight loss (up to 24.2%) and improve metabolic parameters, but they significantly increase the risk of delayed gastric emptying and perioperative pulmonary aspiration.

If you take semaglutide or tirzepatide, tell your anesthesiologist. These drugs slow down your stomach, which increases the risk of vomiting and inhaling stomach contents during surgery, even if you feel fine. You may need to stop the drug a week before surgery, or your procedure might be delayed. Do not assume standard fasting rules are enough.

Tirzepatide improves kidney function markers (eGFR decline and albuminuria) and may slow the progression of chronic kidney disease in patients with type 2 diabetes.

Tirzepatide may help protect your kidneys by slowing the decline in kidney function and reducing protein in the urine, which is beneficial for long-term kidney health in diabetes.

In patients with heart failure and reduced ejection fraction (HFrEF), a BMI greater than 27 kg/m² is associated with significantly higher risks of cardiovascular mortality, heart failure hospitalization, and composite adverse outcomes compared to a BMI of 24–27 kg/m².

If you have heart failure with reduced ejection fraction, maintaining a BMI between 24 and 27 kg/m² is associated with better survival and fewer hospitalizations than having a BMI over 27. This is especially true if your heart failure is caused by coronary artery disease (ischemic). You should discuss weight management strategies with your cardiologist, as higher BMI may increase your risk of cardiovascular death and hospitalization.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists significantly reduce major adverse cardiovascular events (MACE), with weight loss acting as the predominant mediator of this benefit compared to blood pressure reduction alone.

If you have type 2 diabetes or obesity and are at high cardiovascular risk, GLP-1RA medications can significantly lower your risk of heart attacks and strokes. The benefit comes largely from the weight loss these drugs cause, rather than just lowering blood pressure. Discuss these options with your doctor, especially if you have resistant hypertension.

Using ambulatory blood pressure monitoring (ABPM) instead of clinic-based measurements reveals a stronger and more consistent cardiovascular benefit from GLP-1RA therapy.

If you are on GLP-1RA therapy, ask your doctor about using ambulatory blood pressure monitoring (ABPM). It may provide a more accurate assessment of your cardiovascular risk and the effectiveness of your treatment compared to standard clinic blood pressure readings.

Incretin-based therapies (GLP-1RA and dual agonists) cause a mild absolute decrease in skeletal muscle mass and strength, but this is offset by a disproportionately larger loss of fat and liver mass, resulting in improved relative muscle-to-body-weight ratios and preserved or enhanced physical function.

If you are using incretin-based medications for weight loss, expect some loss of absolute muscle mass, but do not panic about 'wasting.' The medication preferentially burns fat and liver fat, which improves your muscle-to-weight ratio. Your strength and endurance often improve because you are carrying less weight. To maximize muscle retention, prioritize resistance training and adequate protein intake, as the drug itself does not protect muscle mass but does not disproportionately destroy it either.

Higher baseline insulin sensitivity is associated with greater retention of lean mass during diet-induced weight loss, but this protective effect is nullified when aerobic or resistance exercise is included in the intervention.

If you are losing weight through diet alone, your metabolic health (insulin sensitivity) dictates how much muscle you keep; those with better sensitivity lose less muscle. However, if you add exercise (especially resistance training), your baseline insulin sensitivity no longer matters for muscle preservation. Exercise protects muscle mass regardless of your metabolic profile, making it the most reliable tool for preserving lean mass during weight loss.

Orlistat, an anti-absorptive medication, produces modest weight loss (2.8-4.8% total body weight loss) by inhibiting gastric and pancreatic lipase.

Orlistat is an oral medication that works by blocking fat absorption, leading to modest weight loss (around 3-5%). It is less effective than newer injectable options and can cause gastrointestinal side effects like oily stools and urgency, which may limit its use.

Preobese individuals with a low relative resting metabolic rate (RMR) normalized for fat-free mass are at higher risk for future weight gain and obesity.

If you are preobese, your metabolic rate relative to your muscle mass might be lower than average, making you more prone to weight gain. Monitoring your metabolic rate or focusing on building fat-free mass could be beneficial strategies for prevention.

Tirzepatide treatment yields greater improvements in physical function for patients with lower baseline physical function scores compared to those with higher baseline scores, despite similar magnitude of weight loss across all baseline levels.

If you have obesity and struggle with physical function (e.g., difficulty walking, climbing stairs), starting tirzepatide is highly recommended. You will likely lose weight just as effectively as someone who is more active, and you may experience the most dramatic improvements in your daily physical capabilities. Do not let current mobility issues stop you from seeking treatment.

Lifestyle interventions (caloric deficit and exercise) remain the cornerstone of obesity care but are often insufficient for long-term maintenance without pharmacotherapy.

Start with a 500-750 kcal daily deficit and 150 minutes of moderate exercise per week. Aim for 5-10% weight loss in 6 months. If you struggle to maintain this, consider adding pharmacotherapy, as lifestyle changes alone are often insufficient for long-term maintenance.

Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain (approx. 2/3 of lost weight within 1-2 years), necessitating chronic use.

Understand that GLP-1 therapy is likely a long-term commitment. If you stop taking the medication, you will likely regain most of the weight you lost. Plan for ongoing management rather than a fixed 'end date' for treatment.

Testosterone therapy (TTh) combined with GLP-1 receptor agonists (GLP-1RAs) and lifestyle modifications constitutes a comprehensive standard of care for obese men with functional hypogonadism, addressing metabolic, vascular, sexual, cognitive, and skeletal health.

For obese men with low testosterone, combining testosterone therapy with GLP-1RA medications (like semaglutide or liraglutide) and lifestyle changes (diet and exercise) is the most effective strategy. This approach not only boosts testosterone but also improves metabolic health, sexual function, and bone density, offering a comprehensive solution to obesity-related hormonal issues.

Patient preferences for GLP-1 receptor agonist outcomes vary substantially by demographic factors (age, sex, BMI), with younger individuals and women expressing significantly higher concern regarding cosmetic side effects like alopecia and severe gastrointestinal outcomes compared to older men.

If you are considering GLP-1 medication, your personal tolerance for side effects matters more than the average patient's experience. Younger women, in particular, may find hair loss or GI issues more distressing than older men. Discuss these specific fears with your doctor before starting, as they significantly impact whether you will stick with the treatment long enough to see benefits.